NCT06099418 - Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | Biotech Hunter

Timeline

Start Date

April 18, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions

HPV-Related Cervical CarcinomaHPV-Related MalignancyCervical Cancer

Interventions

BIOLOGICAL

VB10.16

"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."

DRUG

Atezolizumab Injection [Tecentriq]

Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.

DRUG

Placebo

Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.